Abstract: Three dimensional nonwoven materials and absorbent articles comprising such materials are disclosed. In one embodiment, an absorbent article may comprise an outer cover, a bodyside liner, an absorbent body, and a nonwoven material coupled to the bodyside liner. The nonwoven material may comprise an apertured zone providing a percent open area for the apertured zone that is greater than about 15%. The nonwoven material may be coupled to liner by a front waist bond forming a front waist bonding region which extends through the apertured zone and a rear waist bond forming a rear waist bonding region, wherein the rear waist bonding region has a length that is between about 2% and about 10% of the material length and the front waist bonding region has a length that is between about 20% and about 50% of the material length.

Abstract: Methods of treating a liver disease or condition, or a symptom thereof, in a subject in need of treatment, are disclosed and described. One method comprises orally administering to a subject, a pharmaceutical composition having an amount of a testosterone, or an ester thereof, sufficient to treat the liver disease or condition, or symptom thereof.

Abstract: Methods of treating a liver disease or condition, or a symptom thereof, in a subject in need of treatment, are disclosed and described. One method comprises orally administering to a subject, a pharmaceutical composition having an amount of a testosterone, or an ester thereof, sufficient to treat the liver disease or condition, or symptom thereof.

Abstract: Disclosed are pharmaceutical compositions and oral dosage forms including capsules containing (17-ß)-3-oxoandrost-4-en-17-yl tridecanoate, and related methods. The capsule fill can include an additive and about 14 wt % to about 42 wt % for androst-4-en-17?-ol-3-one esters that comprise (17-ß)-3-oxoandrost-4-en-17-yl tridecanoate or a combination of (17-ß)-3-oxoandrost-4-en-17-yl undecanoate, (17-ß)-3-oxoandrost-4-en-17-yl dodecanoate, and (17-ß)-3-oxoandrost-4-en-17-yl tridecanoate. A single oral administration to a male subject of one or more dosage forms with a total androst-4-en-17?-ol-3-one equivalent dose of about 150 mg to about 895 mg is provided. In another embodiment, a method for providing a serum concentration of androst-4-en-17?-ol-3-one within a target PK performance for a male subject is provided.

Abstract: Three dimensional nonwoven materials and absorbent articles comprising such materials are disclosed. In one embodiment, an absorbent article may comprise an outer cover, a bodyside liner, an absorbent body, and a nonwoven material coupled to the bodyside liner. The nonwoven material may comprise an apertured zone providing a percent open area for the apertured zone that is greater than about 15%. The nonwoven material may be coupled to liner by a front waist bond forming a front waist bonding region which extends through the apertured zone and a rear waist bond forming a rear waist bonding region, wherein the rear waist bonding region has a length that is between about 2% and about 10% of the material length and the front waist bonding region has a length that is between about 20% and about 50% of the material length.

Abstract: Methods of treating a liver disease or condition, or a symptom thereof, in a subject in need of treatment, are disclosed and described. One method comprises orally administering to a subject, a pharmaceutical composition having an amount of a testosterone, or an ester thereof, sufficient to treat the liver disease or condition, or symptom thereof.

Abstract: Methods of treating a liver disease or condition, or a symptom thereof, in a subject in need of treatment, are disclosed and described. One method comprises orally administering to a subject, a pharmaceutical composition having an amount of a testosterone, or an ester thereof, sufficient to treat the liver disease or condition, or symptom thereof.

Abstract: Methods of treating a liver disease or condition, or a symptom thereof, in a subject in need of treatment, are disclosed and described. One method comprises orally administering to a subject, a pharmaceutical composition having an amount of a testosterone, or an ester thereof, sufficient to treat the liver disease or condition, or symptom thereof.

Abstract: Methods of treating a liver disease or condition, or a symptom thereof, in a subject in need of treatment, are disclosed and described. One method comprises orally administering to a subject, a pharmaceutical composition having an amount of a testosterone, or an ester thereof, sufficient to treat the liver disease or condition, or symptom thereof.

Abstract: The invention relates to methods and compositions for the treatment or prevention of Flaviviridae infections. In particular, the invention relates to an LSD1 inhibitor for use in treating or preventing Flaviviridae infections, including hepatitis C virus infections.

Abstract: The invention relates to methods and compositions for the treatment or prevention of Flaviviridae infections. In particular, the invention relates to an LSD1 inhibitor for use in treating or preventing Flaviviridae infections, including hepatitis C virus infections.